Lifitegrast-associated adverse events considered ‘mild to moderate’

Findings from the SONATA study suggest that Shire’s lifitegrast dry eye treatment is well tolerated by patients with an “excellent” safety profile, according to Eric D. Donnenfeld, MD, one of the study investigators.The phase 3 multicenter, randomized, prospective, doubled-masked, placebo-controlled study involved 331 participants with moderate dry eye disease who were randomized 2:1 to receive lifitegrast ophthalmic solution 5% or placebo. Patients administered drops twice daily for a year.